Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s traded shares stood at 1.01 million during the last session, with the company’s beta value hitting 0.09. At the close of trading, the stock’s price was $0.67, to imply an increase of 8.44% or $0.05 in intraday trading. The KPTI share’s 52-week high remains $1.95, putting it -191.04% down since that peak but still an impressive 13.43% since price per share fell to its 52-week low of $0.58. The company has a valuation of $84.80M, with an average of 0.72 million shares in intraday trading volume over the past 10 days and average of 901.99K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Karyopharm Therapeutics Inc (KPTI), translating to a mean rating of 1.57. Of 2 analyst(s) looking at the stock, 0 analyst(s) give KPTI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information
After registering a 8.44% upside in the last session, Karyopharm Therapeutics Inc (KPTI) has traded red over the past five days. The 5-day price performance for the stock is 1.76%, and -13.84% over 30 days. With these gigs, the year-to-date price performance is -0.64%. Short interest in Karyopharm Therapeutics Inc (NASDAQ:KPTI) saw shorts transact 19.8 million shares and set a 17.52 days time to cover.
The extremes give us $3 and $14 for target low and target high price respectively. As such, KPTI has been trading -1989.55% off suggested target high and -347.76% from its likely low.
Karyopharm Therapeutics Inc (KPTI) estimates and forecasts
Looking at statistics comparing Karyopharm Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Karyopharm Therapeutics Inc (KPTI) shares are -22.85% down over the last 6 months, with its year-to-date growth rate higher than industry average at 33.60% against 18.00%.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 16.79% for the past 5-year period. While 2025 is set for a 45.03% return in earnings, projections for the next 5 years are at 24.25% annually.
KPTI Dividends
Karyopharm Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s Major holders
Karyopharm Therapeutics Inc insiders hold 6.20% of total outstanding shares, with institutional holders owning 47.36% of the shares at 50.50% float percentage. In total, 47.36% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 7.65 million shares (or 6.6299% of shares), all amounting to roughly $6.64 million.
The next major institution holding the largest number of shares is PALO ALTO INVESTORS LP with 5.1 million shares, or about 4.4192% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $4.43 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. as the top two Mutual Funds with the largest holdings of the Karyopharm Therapeutics Inc (KPTI) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 3.42 shares. This is just over 2.71% of the total shares, with a market valuation of $2.3 million. Data from the same date shows that the other fund manager holds a little less at 2.01, or 1.59% of the shares, all valued at about 1.35 million.
